Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2005 by Hadassah Medical Organization.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Beth Israel Deaconess Medical Center
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00262093
First received: December 4, 2005
Last updated: March 19, 2007
Last verified: November 2005
  Purpose

The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.


Condition
Pre-Eclampsia

Study Type: Observational
Study Design: Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment: 200
Study Start Date: November 2005
Detailed Description:

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.

We intend to check the angiogenesis profile of primiparas as compared to multiparas.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Every delivery

Exclusion Criteria:

  • Preeclampsia or pregnancy induced hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00262093

Contacts
Contact: Yuval Bdolah, MD, MSc 972-2-5844111 ybdolah@hadassah.org.il
Contact: Hadas Lemberg, PhD 972-2-6777572 lhadas@hadassah.org.il

Locations
Israel
Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91240
Contact: Arik Tzukert, DMD    972 2 6776095    arik@hadassah.org.il   
Contact: Hadas Lemberg, PhD    972 2 6777572    lhadas@hadassah.org.il   
Principal Investigator: Yuval Bdolah, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Beth Israel Deaconess Medical Center
Investigators
Principal Investigator: Yuval Bdolah, MD, MSc Hadassah-Hebrew University Medical School
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00262093     History of Changes
Other Study ID Numbers: PRIMIMULTI-HMO-CTIL
Study First Received: December 4, 2005
Last Updated: March 19, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
preeclampsia
sFlt1
PlGF
parity
angiogenesis

Additional relevant MeSH terms:
Eclampsia
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications

ClinicalTrials.gov processed this record on July 26, 2014